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Background: Hereditary breast and ovarian cancer (HBOC) syndrome is an autosomal 
dominant inherited disorder that include 5–7% of all breast cancer (BC) cases and 10-15% 
of all ovarian cancer (OC) cases. BRCA1 and BRCA2 are the most common genes 
associated to HBOC syndrome. However, hereditary syndrome could be associated with 
germline PVs in several high- and moderate-risk genes. In recent years, Next-Generation 
Sequencing (NGS) has allowed to study multiple genes simultaneously, to reduce analysis 
costs, to led to an explosion of genetic data, and to offer more information to patients. 
Methods: We retrospectively collected and analyzed to BRCA1/2 test 876 patients affected 
by BC and OC (531 of BC, 345 of OC) among January 2016 to August 2020. Successively, 
we analyzed 192 patients resulted BRCA1/2 negative with a strong personal and/or family 
history to BC and/or OC by using Multi-gene panel testing. We evaluated 22 genes involved 
in risk of hereditary breast, ovarian and colorectal cancer, and other inherited tumor 
syndromes. 
Results: Analysis conducted with multi-gene panel testing revealed that 28 (14.6%) BC and 
OC patients showed PVs/LPVs in genes no-BRCA. In particular, we analyzed 165 BC 
patients and 27 OC patients, and we obtained 27 and 4 patients with PVs/LPVs in genes 
no-BRCA respectively. BC patients with alteration in gene over BRCA hardly showed TNBC 
than patients with BRCA1/2 or all wt. Moreover, among BC patients with genes altered 
beyond BRCA the 45.8% showed a Bilateral Breast Cancer. In OC group we observed that 
75% of patients with PVs/LPVs in genes over BRCA showed a previously personal history 
of BC or other cancer. 
Conclusion: Our analysis showed that the 14.6% of patients BRCA-negative with a strong 
personal and/or family history to BC and/or OC presented alteration in genes beyond 
BRCA1/2. This result highlighted the importance of multi-gene panel testing which should 
























Many patients affected by Hereditary Breast and Ovarian Cancer (HBOC) syndrome with a 
strong personal and/or family history to BC and/or OC that result negative for BRCA1 or 
BRCA2 pathogenic variants, need a further genetic testing through a multi-gene panel. 
Some patients with negative test result for BRCA1/2 pathogenic variants may harbour 
pathogenic variants or likely pathogenic variants in several high- and moderate-risk genes, 
including ATM, CHEK2, PALB2, PTEN, TP53, STK11. Of course, the use of multi-gene 
panel provides clinicians more information compared to single testing and is recommended 
to reduce time and costs of analysis. Therefore, we focused on the potential clinical impact 
of NGS-based multi-gene panel testing in HBOC patients with a strong personal and/or 
family history to BC and/or OC, in order to evaluate the utility of perform a most 
comprehensive genetic analysis in these subjects. Our study revealed that the use of NGS-
based multiple-gene panel testing could increase the detection rates of germline alterations 
in these patients. Indeed, a significant proportion (14.6%) of PVs/LPVs was found with the 
aim to offer specific risk-reducing measures and free prevention programs for patients and 



































During the 19s century, many studies allowed to understand women from specific families 
were prone to develop breast and ovarian cancer [1]. Peoples that shown this predisposition 
ware identify with Hereditary breast and ovarian cancer (HBOC) syndrome, an autosomal 
dominant inherited disorder that include 5–7% of all breast cancer (BC) cases and 10-15% 
of all ovarian cancer (OC) cases [2]. Patients with HBOC syndrome may have an increased 
risk of developing other types of cancer such as pancreatic cancer, prostate cancer, and 
melanoma. Until date National Comprehensive Cancer Network (NCCN) established clinical 
guidelines to distinguish HBOC patients [3].  
In worldwide, lung cancer represent the most commonly diagnosed cancer and the main 
cause of cancer death in both sex [4]. However BC and OC are in the top ten of the most 
common cancer for incidence and mortality in females [5]. BC represents the most 
diagnosed tumours in females [6]. In general, different environmental and genetic risk 
factors influenced BC and OC. Furthermore, the majority of BC and OC showed sporadic 
nature (75-80%), about 15-20% was considered familial-type and 5-10% was hereditary [7]. 
In this contest, BRCA1 and BRCA2 are the most common genes associated to HBOC 
syndrome showing a germline pathogenic variant (PV) or likely-pathogenic variant (LPV). In 
fact, the risk to develop breast cancer was observed into 50–85% BRCA1 and BRCA2 
carriers, while to ovarian cancer BRCA1 and BRCA2 carriers were characterised by a risk 
of 15–45% and 10–20% respectively [7]. However, hereditary syndrome could be associated 
with germline PVs in several high-risk genes such as CDH1, PALB2, PTEN, STK11, TP53, 
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or moderate-risk genes like ATM, CHEK2, BARD1, BRIP1, RAD51C, RAD51D [8]. 
In recent years, Next-Generation Sequencing (NGS) has allowed to study multiple genes 
simultaneously, to reduce analysis costs, to led to an explosion of genetic data and to offer 
more information to patients. 
 
1.1.1 Breast cancer 
 
The most common cancer’s type in female was the breast cancer, with one out of eight 
women developing a BC during lifetime [9].  
BC represent about 30% of cancers in women worldwide at any age, with a higher incidence 
in the most economically advanced States. BC is the most frequently diagnosed and also 
the leading cause of cancer death at any age. However, mortality rate is constantly 
decreasing probably to major diffusion of screening and prevention programs associated at 
analyzes of BRCA1/2 genes.  
BC is a multifactorial disease involving lifestyle, hormonal balance and inherited 
predisposition [10] Different factors are implicated in the development of BC, like as sex, 
age and family history. Females show a 100 times greater risk than men; in fact, male breast 
cancer represent <1% of all breast cancer diagnosed. The most frequent new diagnoses 
were revealed at an age >55 years old. This correlation is probably related to steroid 
hormones that act in continuous during lifetime, progressive DNA damage and epigenetic 
modification [11]. The 5-10% of all BC are considered as hereditary and they are related to 
BRCA1 and BRCA2 genes. Over the past decades, an increase of risk to develop BC is 
associated with a confirmed family history of BC cases. Moreover, hereditary tumor are often 
bilateral and an early age onset. 
Based on molecular and histological features, BC could be divided into five major subtypes: 
luminal A, luminal B, luminal/human epidermal growth factor receptor 2 (HER2), HER2 
enriched, and triple negative (TNBC) which includes, only in part, the basal like subtype [12]. 
Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 with Ki67 represent most 
valid and widely used biomarker in BC and they are evaluated directly in tumor tissue. 
Seeing as tumor tissue employment is difficult, validated circulating biomarkers as TPS, 
CEA, and CA 15-3 are necessary to use. However, to date, these biomarkers cannot serve 
as prognostic biomarker but have a potential negative predictive role in BC patients.  
The most relevant predictive biomarker in BC patients is ER, its used as marker for 
endocrine therapy and its theorized that ER level are correlated to the positive effect of 
antiestrogenic therapy [13].  
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Another frequently assessed biomarker in BC is PR that is related to ER because PR could 
be induced by estrogen. Moreover, ER and PR evaluation are strongly recommended for 
BC patients management [14]. 
In addition to ER and PR, another predictive biomarker is HER2. High expression of HER2 
is correlated to metastasis, invasion, and tumor cells proliferation [15]. 
About 60–70% of BC cases in premenopausal women was BC-hormone receptors positive 
(HR+). Therapeutic approach chosen to these patients was hormonotherapy employing 
tamoxifene to estrogen blockade and aromatase inhibitors (anastrozole or exemestane) to 
prevent hormone production from ovary [16]. Endocrine therapy was the best treatment to 
patients with BC HR+ and HER2-negative regardless the use of cyclin-dependent kinase 4 
and 6 (CDK4/6) inhibitors [17] and independently of BRCA status. 
HER2+ represents approximatively the 20% of all BC. These patients were treated with a 
combination of chemotherapy and anti-HER2 monoclonal antibody therapy [18]. 
TNBC represent about 10-20 % of all BC, it is especially proliferative and aggressive 
characterized by poor prognosis than other BC type for patients. It is defined 
immunohistochemically as breast cancer that does not excessively express HER2 and is 
negative for ER and PR [19]. TNBC is classified in six categories: basal-like 1 (BL-1), basal-
like 2 (BL-2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem cell-like 
(MSL), luminal androgen receptor (LAR). TNBCs treatment was most difficult than other BC 
types, yet the chemotherapy was the gold standard nowadays. However, the combination 
of chemotherapy with recombinant humanized monoclonal antibody against Vascular 
Endothelial Growth Factor (VEGF) represented a valid treatment alternative [20] [21]. 
TNBC are often characterized by PVs/LPVs in BRCA1 gene and pathological features 
determine frequently a infiltrating ductal carcinomas subtype with high grade and geographic 
necrosis [10]. While BC exhibiting PVs/LPVs in BRCA2 gene showed features like sporadic 
BC with 2/3 grade carcinomas, ER+, PR+ and HER2- [22]. 
Besides standard anthracycline- and taxane-based chemotherapy, recent studies have 
better elucidated the potential role of platinum agents in patients with BRCA-mutated breast 
cancer. 
Recently, the Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) discovery has 
offered new therapeutic choices to patients affected by BRCA-mutated ovarian, breast and 
pancreatic cancer. Robson and colleagues in OlympiAD study demonstrated that in patients 
with HER2-negative metastatic breast cancer and a germline BRCA mutation have a 
significant increase in progression-free survival (PFS) when treated with Olaparib, a poly 
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adenosine diphosphate-ribose polymerase inhibitor (PARPi), monotherapy rather than with 
standard therapy. However, death was 42% lower than patients treated with standard 
therapy in this setting of patients [23].  
In 2019, Robson et al. reported the final Overall Survival (OS) in the OlympiAD study. A 
statistically significant improvement in patients treated with Olaparib was not observed 
compared to chemotherapy standard. A greater increase in OS were presents when patients 
not received chemotherapy before Olaparib treatment [24]. 
In BrighTNess study patients are randomized at adjuvant treatment with carboplatin versus 
carboplatin and Veliparib versus chemotherapy standard. The veliparib/carboplatin 
combination showed a higher pathological complete response (pCR) rate than standard 
treatment also in patients with PVs/LPVs in BRCA1/2 genes [25].  
In 2017, EMBRACA study led to the registration of Talazoparib, another PARPi, by FDA. 
The authors compare Talazoparib with standard therapy in women affected by BC HER2- 
and PVs/LPVs in BRCA1/2. The primary endpoint was the PFS, that was statistically 
significant in women treated with Talazoparib (8.6 months vs 5.6 months) [26]. In 2020 the 
authors evaluate the final OS that not result significantly improve in Talazoparib arm 
compered to chemotherapy [27]. 
Andrè and colleagues shown that patients HR-positive HER2-negative advanced breast 
cancer with PIK3CA-mutation have a significant improvement in progression-free survival 
and better overall response by adding an α-specific PI3K inhibitor to standard treatment [28]. 
 
1.1.2 Ovarian cancer 
 
Ovarian cancer is the third gynaecological cancers diagnosed after cervical and uterine and 
the fifth cause death in women [29][30].  
Considering the morphology, OC are divided in epithelial and non-epithelial origin; the 
epithelial represented about 90% of all OC [31][32]. Epithelial types are histologically 
classified in serous (52%), endometrioid (10%), mucinous (6%), or clear cell (6%), and the 
remaining 25% are rare or unspecified. Among them, clear cells and mucinous are less 
frequent but have a higher mortality, compared to other types [33]. 
Moreover, epithelial cancers are divided in I type and II type by clinicopathologic features 
[34]. Type I are low-grade, unilateral and cystic tumours. Usually, these OC originate from 
extraovarian benign lesions that acquire a phenotype malignant after mutations [35].  
Type II includes high-grade serous carcinomas; the most common OC subtypes are high-
grade, bilateral and particularly aggressive. Women with high-grade OC often present 
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extraovarian disease and ascites [34]. 
Epithelial ovarian cancer (EOC) is known to have a poor prognosis because it’s diagnosed 
at advanced stage, in most cases is asymptomatic and usual symptoms are often unspecific. 
Today, the primary prognostic factor remains to anticipate the stage at diagnosis. A study 
estimating a combination of gynaecological ultrasonography and Ca125 testing has not led 
to a strong mortality decrease but additional follow-up was required [36]. Currently, the 
strategy for advanced stage OC is primary debulking surgery followed by standard therapy. 
Treatment standard is platinum-based and provides six cycles of carboplatin plus paclitaxel 
every 3 weeks [37]. In the past few years, different studies led to approval of bevacizumab 
adding to standard therapy and in maintenance in EOC patients with improves PFS [38], 
[39]. 
The most common risk factor to OC is represented by family history of breast and/or ovarian 
cancer with a genetic predisposition determined by BRCA1 and BRCA2 in 25% of OC 
affected women [30], [40]. BRCA test is fundamental at moment of OC diagnosed, indeed 
BRCA have a role to estimate the cancer treatment efficacy. In the past years three different 
groups showed that OC patients with a germline BRCA1/2 PV exhibited an improved 
sensitivity to platinum derivatives therapies [41]–[43].  
Recently, Moore et al. in SOLO-1 trial demonstrated that women with OC and germline or 
somatic PV in BRCA1/2 have an improvement in terms of PFS when treated with Olaparib 
as maintenance after response to first-line platinum-based chemotherapy [44]. Besides 
SOLO-1 trial, other studies have shown statistically significant results regarding treatment 
with PARPi in OC patients.  
PAOLA-1 trial demonstrated that treatment with Olaparib and bevacizumab as first-line 
maintenance therapy have shown an improvement in PFS regardless BRCA status [45]. In 
VELIA trial women affected by OC with BRCA mutations showed a largest benefit in term of 
PFS when treated with veliparib and chemotherapy combination and subsequently veliparib 
as maintenance [46].  
Females with OC presents germline PVs/LPVs in genes beyond BRCA1/2 belonging to the 
Homologous Recombination (HR) pathway or mismatch repair (MMR) pathway. HR status 
was used as stratification factor in PRIMA trial. This trial proves that OC patients with 
Homologous Recombination Deficiency (HRD) treated with Niraparib have significant 
clinical benefit over placebo [47]. The presence of PVs/LPVs in MMR genes were reported 
in 10-12% of all histological subtypes; these patients could be treated with pembrolizumab 
[30]. In this contest, a multigene panel testing with genes involved in HR and MMR pathways 
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is recommended to evaluate germline PVs/LPVs and to offer the best therapeutic choice for 
HBOC patients.  
 
1.1.3 Genetic counselling 
 
Genetic counselling consists of multidisciplinary team composed by oncologist, geneticist 
biologist or medical, psychologist and tumor patients affected named proband. During 
counselling, geneticist and proband trace patient personal and family history through the 
family tree reconstruction. In families where is the geneticist highlighted a suspected 
hereditary transmission, the identification of PVs/LPVs carriers is necessary. Once identified 
a PVs/LPVs in proband, the variant research is extended to family members. 




Table 1. Criteria to Genetic Counselling in patients affected by Breast and Ovarian Cancer 
Personal History of 
Male Breast Cancer 
Women with Breast and Ovarian Cancer 
Women with Breast Cancer <36 years  
Women with TNBC <60 years 
Women with Bilateral Breast Cancer <60 years 
Personal History of Breast Cancer <50 years and first-degree family members 
affected by 
Breast Cancer <50 years 
Non-Mucinous And Non Borderline Ovarian Epithelial Carcinoma At Any Age 
Bilateral Breast Cancer 
Male Breast Cancer 
Personal History of Breast Cancer >50 and almost 2 first-degree family members 
with Breast or Ovarian Cancer 
Personal History of PVs/LPVs in Breast and Ovarian Cancer Susceptibility Genes 
 
Genetic test results are:  
-informative: PVs/LPVs is identified; 
-non informative: PVs/LPVs is not identified but it cannot be excluded that it is present, or in 
genetic test is identified a Variant of Unknown Significance (VUS); 
-negative: only when a PVs/LPVs identified in a proband but it is not present in family 
member.  
Variant classification is based on different criteria developed by the Evidence-based 
Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium 
(https://enigmaconsortium.org/) and according to IARC recommendations [48]. Therefore, 
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detected genetic variants were divided into five classes: 
-class I (benign); 
-class II (likely benign); 
-class III (VUS); 
-class IV (likely pathogenic); 
-class V (pathogenic). 
 
1.1.4 Homologous Recombination Pathway 
 
It has been estimated that cells develop thousands of DNA damage every day [49], because 
the DNA is frequently exposed at different agents exogenous and/or endogenous. 
Therefore, normal cells present several DNA repair mechanisms including nucleotide 
excision repair (NER), base excision repair (BER), mismatch repair (MMR), homologous 
recombination repair (HRR), and non-homologous end joining (NHEJ) [50]. HRR and NHEJ 
are the principal pathway implicated in repair of double stranded DNA breaks (DSBs).  
NHEJ which happens during G0/G1 cell cycle phase is an error prone pathway that does 
not use intact sister chromatid as a template. Therefore DNA break ends are directly ligated 
among them causing small insertions or deletions [51], [52]. 
HRR occurs in proliferating cells during late S and G2 phases of cell cycle; it is a highly 
conserved pathway that allows DNA DSBs repair in an accurate manner based on sister 
chromatid as template [53]. BRCA1/2 are the main proteins involved in HRR pathway. When 
cells are BRCA1/2 deficient, the repair of DNA is based on Non-Homologous End Joining 
which determines an increase of DNA errors and genomic instability [54].  
In this contest, polyADP-ribosylation (PARylation) represent a crucial post-translational 
protein modification involved in DNA damage repair [55]. In human cell, PARylation is 
catalysed by poly(ADP-ribose) polymerases (PARPs) which is composed by 17 members 
[56]. Among 17 members, PARP-1, PARP-2 and PARP-3 are implicated in DNA damage 
response, while PARP-5a and PARP-5b, also called tankyrase-1 and tankyrase-2, are 
involved to maintain genomic stability. 
PARP-1 is the most famous and most common studied PARP members implicated in PAR 
chains synthesis. PARP-1 use NAD+ as substrate to catalyse the unit transfer of ADP-ribose 
(ADPR) moieties onto different nuclear proteins [57]. In normal cells, PAR chains are 
degraded by PAR glycohydrolase (PARG) with exoglycosidic and endoglycosidic activities, 
or through ADP-ribosylhydrolase 3 (ARH3) with only exoglycosidase activity. When PAR 
chains cannot be hydrolyzed, the excessive presence of protein-free PAR chains induce cell 
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death through a form of programmed cell death named parthanatos [58]. 
PARP-1 contains 6 domains. Only two domains do not have known function (C and E 
domains). Domain A is DNA-binding domain with two zinc-finger necessary to interact with 
DNA breaks. Domain B contain a nuclear localization signal (NLS) essential to PARP-1 
nuclear transport [59]. Domain D is needful to interface to different nuclear partners through 
BRCT motif. Domain F show a catalytic activity [60]. 
PARP-2 is a nuclear protein that interacts with PARP-1 sharing proteins involved in Single 
Strand Break Repair (SSBR) and Base Excision Repair (BER). PARP-2 catalytic domain 
shown a 69% similarity with PARP-1, while DNA-binding domain is different.  
PARP-3 is a centrosome component  able to interact with PARP-1, with which shares two 
domains with 61% of similarity [61]. 
PARylation process intervenes in DNA repair pathway in both SSBs and DSBs. In presence 
of SSBs, PARP-1 cooperate with SSBR factor X-ray repair cross-complementing protein 1 
(XRCC1) trough BRCT domain assembling SSBR machinery [62]. 
Schultz et al. in 2003 shown that PARP-1 is not indispensable for HR; in addition, PARylation 
seems to have a small effect on HR in PARP-depleted cells [63]. 
Nevertheless, PARP-1 has been associated with HR-repair, the reactivation of replication 
fork trough recruitment of MRE11, and RAD51 promoting the correct DNA replication [64], 
[65]. 
PARPi act by synthetic lethality mechanism against cancer with HRD. Synthetic lethality 
happens when cell death is caused by a simultaneous disruption of two genes [66]. In HRD 
situation (for example in BRCA-mutated cells), PARP inhibition led to replication fork 
collapse that cannot be repaired because the HR activity is disrupted and so cell death 
occurs [67] (Figure 1). 
Homologous recombination pathway is composed, over BRCA1/2, by a multitude of other 
DNA repair proteins such as ATM, CHEK2, BARD1, BRIP1, MRE11, RAD50, NBN, 
RAD51C, RAD51D, and PALB2 (Figure 2). In presence of DNA damage, BARD1 identifies 
PAR chain and recruits BRCA1/BARD1 heterodimer to promote efficient HR [54]. Another 
complex included in HR is MRN complex composed by MRE11, RAD50 and NBN proteins, 
which serves to cut DSBs ends. This complex is essential to signal DNA damage and to 
stimulate Ataxia Telangiectasia Mutated (ATM) protein that provide to process DSBs in 
SSBs [53]. BRCA2 regulates RAD51 and its paralogues (RAD51B, RAD51C and RAD51D) 
that searching sequence homology on the sister chromatid to use as a reference. PALB2 
interact with BRCA2 and BRCA1. BRCA2 is regulated by PALB2 that enables nuclear 
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localization of BRCA2 in DNA damage sites [51], [68], [69]. Instead BRCA1 controls PALB2-
dependent loading of BRCA2-RAD51 repair machinery at double stranded DNA breaks [70]. 
BRCA1‑interacting protein carboxy‑terminal helicase1 (BRIP1) is also suggested to be 
involved in HRR by recruiting BRCA1 to DSBs. 
One of major problems in PARPi treatment is the develop of acquired resistance following 
an initial responsiveness to therapy. The principal mechanism of resistance to PARPi is 
restoring HR capacity, DSBs are repaired and tumor cell continues to survive. HR capacity 
is restored by two mechanisms: the suppression of NHEJ activity, and BRCA1/2 reactivation 
through reverse mutation [66].  
NHEJ can be suppressed by 53BP1 depletion that saves BRCA mutated cells and reduce 
hypersensitivity to PARPi [71]. Another mechanism to suppress NHEJ pathway is 
represented by the inhibition of REV7, that stimulate NHEJ through shRNA promoting HR 
activity [72].  
The main known system to restore HR is the reactivation of BRCA1/2 by secondary 
mutations, that restored the Open Reading Frame (ORF) of BRCA genes. Several studies 
confirmed that reverse mutations are present in patients with germline and/or somatic 
BRCA1/2 PVs/LPVs [73] and decrease of PFS during Rucaparib treatment from 9 to 1.8 
months [74] 
 
1.1.5 High Penetrance Genes 
 
BRCA1 and BRCA2 
The two major genes involved in HBOC syndrome are BRCA1 and BRCA2, two tumour 
suppressors developed in 1994 [75] and 1995 [76] respectively. Pathogenic Variants/Likely 
Pathogenic Variants identified in BRCA1/2 are inherited in autosomal dominant manner and 
lead to an increased risk to develop HBOC syndrome.  
BRCA1 gene (17q21) is discovered in 1994 by Miki et al.; it is composed by 24 exons of 
which 23 codificant a protein involved to different cellular process such as DNA-repair, cell-
cycle arrest and genomic stability [75]. This protein contains a RING domain at N-terminal, 
a central region composed for majority by exons 11-13, and BRCT domain at C-terminal. 
RING domain is composed by a RING finger and two alpha helices in exons 2-7. RING 
structure is stabilized by two Zn2+ atoms, organized by Zn2+-binding loops through seven 
conserved cysteine residues and one conserved histidine residue [77]. BRCA1 interact with 
BARD1 (BRCA1 Associated RING Domain protein 1) via N- and C-terminal helices in RING 
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finger. This interaction increases BRCA1 ubiquitin ligase activity and hidden the nuclear 
export sequence (NES) of both BRCA1 and BARD1 to retain both proteins in nucleus [78]–
[80]. 
Region between exons 11 and 13 cover more than 65% of all BRCA1 protein and codify for 
two nuclear localization sequences (NLS) and binding sites for different proteins such as 
retinoblastoma protein (RB), C-MYC, RAD50 and RAD51 involved in several cellular 
pathways. This portion includes a part of a coiled-coil domain which mediates interactions 
with PALB2, a protein involved in in DNA damage repair with RAD50 and RAD51 genes 
[81]. 
BRCA1 C-terminal (BRCT) domain is a conserved domain in several proteins including 
BRCA1. BRCT domain regulates the interaction between BRCA1 and proteins 
phosphorylated by ATM and ATR induced by DNA damage. Based on capacity to recognize 
phosphoproteins, BRCT domains are divided in two types: class I that identify 
phosphoserine (pSer) residues, and class II that recognize both pSer and phosphothreonine 
(pThr) residues [82]. 
BRCA2 gene (13q12-q13) is discovered in 1995 by Wooster et al. It consists of 27 exons of 
which 26 codificant a protein involved in repair of DNA double-strand break by Homologous 
Recombination pathway. Protein structure is composed by PALB2 bond site at N-terminal, 
eight BRC repeats that bind with different affinity RAD51, a DNA binding domain (DBD) that 
recognize single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA). In the C-
terminal  are presents a nuclear localization sequence (NLS) and the bond site for RAD51 
mediated by CDK activity [83]. 
TP53 
TP53 gene located on 17p13.1 encodes a tumor suppressor that regulate several cellular 
processes such us cell cycle arrest, apoptosis, senescence and DNA repair. For all these 
reasons, tp53 is named “the guardian of the genome” and indeed the 50% of sporadic 
tumors showed a somatic mutation in TP53 gene [84]. 
Germline PVs/LPVs detected in TP53 gene are associated with autosomal dominant 
disorder, characterized by a high predisposition to different types of cancer, called Li-
Fraumeni syndrome [85]. Patients that exhibiting this syndrome have a risk increase to 





PTEN gene is located on 10q23.31. The protein is a phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase that negatively regulates the MAPK (Mitogen-Activated 
Protein Kinase) pathway through its protein phosphatase activity [88]. In PTEN gene the 
presence of germline PVs/LPVs are related to Cowden syndrome, an autosomal dominant 
disorder characterized by benign hamartomas and an increased risk to develop breast, 
thyroid, uterine, and other cancers [89]. Indeed, in patients with PVs/LPVs in PTEN gene, 
the risk during lifetime to develop a BC is estimated in around 25–85%, while for OC the risk 
is low or none [90]. 
STK11 
STK11 gene is located on chromosome 19p13.3 and encodes a protein with 
serine/threonine kinase activity. Germline PVs/LPVs are correlated with Peutz-Jeghers 
syndrome, an autosomal dominant disorder described by melanocytic macules, 
gastrointestinal hamartomatous and a predisposition to develop different cancer types. In 
particular, patients with PV/LPVs in STK11 gene have an increased risk to develop BC and 
gynaecological cancers estimated in 32–54% and 13% respectively [91]. 
CDH1 
CDH1 is positioned on chromosome 16q22.1 and encodes E-cadherin involved in different 
cellular process including prevents invasiveness and metastatization [92]. An autosomal 
dominant condition called Hereditary Diffuse Gastric Cancer syndrome is related to germline 
PVs/LPVs in the CDH1 gene. This syndrome predisposes to diffuse-type gastric cancer and 
lobular breast cancer, with a risk of 39–52% to develop a BC [93]. 
 
1.1.6 Moderate and Low Penetrance Genes 
 
PALB2 
PALB2 gene is located on 16p12.2 and encodes protein that collaborates with BRCA2 in 
HR pathway, binding SSBs and directly interacts with RAD51 to stimulate strand invasion in 
HR process. PALB2 PVs/LPVs are recently related to an increase in BC risk of about 50% 
for females and 1% for man, and a low risk of OC and pancreatic cancer respectively of 5% 




BRIP1 gene is positioned on chromosome 17q23.2 and encodes a protein with DNA 
helicase activity that binds directly BRCA1 at BRCT repeats. BRIP1 PVs/LPVs are 
associated with a higher risk of OC assessed of about 6%, while BC risk is low or none [95]. 
ATM 
ATM gene is located on 11q22.3 and is composed by 66 exon that codifies to 3056 amino 
acids [96]. ATM is a serine/threonine protein kinase, discovered in 1995 by Savitsky et al., 
implicated in developed of an autosomal recessive condition named Ataxia-Telangiectasia 
[97]. Few years later, in 1998 two different group showed that ATM is also involved in DNA 
damage repair and has been implicated in an increase of ∼2-fold risks of breast cancer. 
Whereby is classified as Moderate-risk BC gene [98], [99]. 
CHEK2 
CHEK2 gene located on 22q12.1, encodes a nuclear Serine/Threonine kinase involved in 
different cellular process [100]. In presence of DSBs, ATM catalyzes the phosphorylation of 
CHEK2 which in turn phosphorylates CDC25C blocking entry into mitosis [101], moreover 
CHEK2 phosphorylates p53 tumor suppressor protein prevents its degradation and stoppes 
cell cycle in G1 phase [102]. Germline PVs/LPVs in CHEK2 gene are related with an 
increased risk of BC estimated to be 25–39% during a lifetime [103]. Risk is modulated by 
family history: in carriers without affected family member the risk is around 20%, and it grows 
up to 44% when both first- and second-degree families are affected [104]. In particular, an 
increase of BC risk of two- to three-fold in women and ten-fold in man was associated a 
variant named c.1100delC in CHEK2 [105]. 
Besides BC risk, PVs/LPVs in CHEK2 has been related to different cancers as well as 
prostate, gastric, colorectal and with much debate OC [5]. 
BARD1 
BARD1 gene localized on chromosome 2q35 is composed of 11 exons.  Produced protein 
consists of 777 amino acids that interacts with N-terminal region of BRCA1 creating a 
heterodimer with ubiquitin E3 ligase activity involved in DNA damage response pathways 
and cell cycle regulation [106]. BARD1 PVs/LPVs has been associated with an increase of 
BC and OC risks, even if there is no clear evidence especially in OC cases [95]. However, 
considering the involvement of BARD1 in HR pathway, clinical trials have been developed 
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to evaluate PARP inhibitors treatment in patients with BC and PVs/LPVs in BARD1 gene 
[85]. 
RAD51 
RAD51 gene encodes a protein involved in Homologous Recombination pathway during 
DSBs; it presents seven different paralogs (RAD51, RAD51B, RAD51C, RAD51D, XRCC2, 
XRCC3, and DMC1). Monoallelic PVs/LPVs in RAD51 and its paralogs have been 
associated to cancer predisposition (in particular RAD51B, RAD51C) and RAD51D in OC, 
while RAD51, RAD51B, and XRCC2 in BC [108]. In particular, RAD51C located on 
chromosome 17q22 is associated with around 7% OC risk, whereas BC risk is debatable 
[109]. Instead PVs/LPVs of RAD51D, located on 17q22, are associated to OC risk around 
15% but BC risk is questionable [110]. 
MRN complex 
The MRN complex is formed by three proteins encoded by MRE11, RAD50, and NBN genes 
implicated in DSBs repair and able to act as tumor suppressors by regulating genomic 
stability [5]. Germline PVs/LPVs in these genes have been associated to an increase in BC 
and/or OC risks [111]. In particular, NBN gene, positioned in 8q21.3, encoded a Nibrin 
protein essential to MRN complex localization, and its interaction with other proteins involved 
in DSBs signaling. PVs/LPVs in NBN gene influence cancer predisposition with an increase 
in BC, prostate cancer, medulloblastoma, and melanoma [112]. 
 
1.1.7 Mismatch repair 
 
Mismatch repair system (MMR) is a type of DNA damage repair responsible to preserve 
genomic stability by correcting spontaneous base-base mispairs and INDELS developed 
during DNA replication. The presence of MMR alteration leads to mutational rate increase 
and high microsatellite instability (MSI) [113]. 
Mismatch repair pathway is composed by 5 proteins that acts as heterodimers: MLH1, 
MSH2, MSH6, PMS2 and EpCAM (a regulator of MSH2). MSH2 gene on chromosome 2p21 
encode to MSH2 protein that heterodimerize with two different partners, MSH6 and MSH3. 
However, MSH2/MSH6 heterodimer is more present than MSH2/MSH3 because MSH6 is 
expressed 10 more times than MSH3 [114]. MSH2/MSH6 function is to detect single base 
mismatches and dinucleotide insertion/deletion and successively to engage additional 
molecules as Proliferating Cell Nuclear Antigen (PCNA), Replication Factor C (RFC), 
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MLH1/PMS2 heterodimer and exonuclease 1 (Exo1) by leading to mismatch final 
dissociation [115]. 
MLH1 gene, located on chromosome 3p21, encode protein that form heterodimer with three 
different monomers, PMS2, PMS1 and MLH3 enrolled after mismatch identification by 
MSH2/MSH6 heterodimer starting the repair process. MLH1/PMS2 contain an endogenous 
endonuclease activity that nick unmethylated strand and provides an access point for EXO1 
nuclease to degradation of DNA strand containing mispaired bases [116]. 
Germline PVs/LPVs in MMR genes determine an autosomal dominant syndrome called 
Lynch Syndrome, that is associated to an increased risk to develop colorectal cancer, 
endometrial cancer, epithelial ovarian cancer, stomach, pancreatic, brain ecc… [117]. This 
syndrome is responsible of about 10–15% of OC; germline/somatic MMR deficiency 
characterize about 1-8% of serous OC. [118]. In particular, OC risk is associated to MLH1 
PVs/LPVs in 10-20% of patients, to MSH2 PVs/LPVs in 17–24%, to MSH6 PVs/LPVs in 8–
13% of patients, and to PVs/LPVs in PMS2 gene the OC risk is analogous to generic 
population [119].  
Considering all these conditions, in 2020 ASCO guideline has been approved treatment with 
pembrolizumab, a monoclonal anti-programmed cell death-1 antibody, in the setting of 
recurrent disease in patients with mismatch repair deficiency independently of primary site 
[30].  
 
1.1.8 Multi-gene Panel Testing in HBOC patients 
 
In patients with HBOC syndrome BRCA1/2 testing is recommended. However, it is 
becoming necessary to study multiple genes in short-time and cost-effective manner. This 
scenario it has become possible with the advent of next-generation sequencing (NGS), 
which allow the simultaneous sequencing of multiple samples and genes, and in particular 
the multi-gene panel testing. To be accepted by scientific community, multi-gene panel 
approach should have a high rate of analytic concordance with more conventional 
sequencing methods as Sanger sequencing and Multiplex Ligation-Dependent Probe 
Amplification (MLPA). Another advantage, besides the cost reduction, is a possible 
therapeutic implementation in patients that showing a PVs/LPVs in genes included in multi-
gene panel rather than single gene testing. Moreover, a germline mutation revealed could 
have an implication not only in therapeutic choice but also in the prevention of patient or in 
an unaffected relative. In 2016, NCCN recommended primary prevention and early detection 
in patients with PVs/LPVs [3]. 
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However, the approach with multi-gene panel showing diverse disadvantages such as an 
increasing of VUS and PVs/LPVs in moderate/low-penetrance genes or with limited clinical 
relevance. These disadvantages can determine a risk overestimation and an increasing 
number of interventions without benefits. 
To reduce this overestimation, the choice of multi-gene panel testing should be guided by 
personal and family history of patients and the multi-gene approach should be offer to 
patients at high risk.  
In the last few years, different studies have focused on multi-gene panel testing use on 
HBOC patients.  
In 2017 Kurian et al. showed an increased BC risk associated with 8 diverse genes ATM, 
BARD1, BRCA1, BRCA2, CHEK2, PALB2, PTEN, TP53 while no mutations in MMR genes 
was associated at BC risk. Moreover, the researcher founded ATM, BRCA1, BRCA2, 
BRIP1, MLH1, MSH6, MSH2, NBN, RAD51C, RAD51D, and STK11 genes strongly 
associated with OC risk. Interestingly, for NBN gene no association was revealed with breast 
and ovarian cancers [120].  
Germani et colleagues, in their study on 733 patients with BC, OC and pancreatic cancer 
(PC) described a PVs/LPVs in 14% of BC/OC patients beyond BRCA1/2 genes, in particular 
CHEK2, RAD51C, ATM, MLH1, MSH2 and RECQL genes. However, the investigators 
showed an elevated presence of VUS in about 20% of patients that often causes problem 
in risk assessment and usually anxiety in patients [121].  
Fanale et al in 2020, study 139 patients with bilateral breast cancer (BBC) and find that 
37.4% have a PVs/LPVs in high- and moderate-penetrance BC susceptibility genes like 
BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, RAD51C. In particular, is showed a strong 
correlation between BBC and LPVs/PVs in PALB2 and CHEK2 genes [8].  
 
1.2 Rationale and objectives 
 
Considering the extensive knowledge about preventive role of BRCA1/2 genes, in the last 
few years BRCA genes hired an important predictive value to therapeutic response. In fact, 
recently FDA approved different PARP inhibitor to treatment of patients affected by BC or 
OC with PVs/LPVs in BRCA1/2 achieving an improve in terms of PSF and OS. BRCA1/2 
genes are involved in pathway of DNA repair named Homologous Recombination together 
other genes like as PALB2, CHEK2, ATM, STK11, TP53. 
Today patients with a strong personal and/or family history to BC and/or OC resulted 
BRCA1/2 negative do not receive new possible therapeutic approaches and a specific risk-
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reducing measures and their family members are not followed with prevention programs. 
However, the advent of NGS before and, in the last few years, the multi-gene panel testing 
gave these families the opportunity to be monitored over time and the possibility of 
accessing new therapeutic frontiers. 
The aim of study was assessed inherited pathogenic variants/likely pathogenic variants in 
both BRCA1/2 genes and other genes involved in Homologous Recombination pathway in 
patients affected by Hereditary Breast and Ovarian Cancer syndrome with multi-gene panel 
approach. The objective of this study was to evaluate the contribution of these alterations, 
showed in high- and moderate-penetrance genes, to identify probands who could benefit 
from PARP inhibitor treatment. Moreover, the identification of variants in genes beyond 
BRCA1/2 suggest family members a specific risk-reducing measures by offering free 


















2.1 Study population 
 
 
We conducted a retrospective study at the “Sicilian Regional Center for the Prevention, 
Diagnosis and Treatment of Rare and Heredo-Familial Tumors” of the Section of Medical 
Oncology of University Hospital Policlinico “P. Giaccone” of Palermo. We collected and 
analyzed all medical information regarding 876 patients divided in 531 women and men with 
primary breast cancer and 345 women with ovarian cancer which were underwent to 
germline and somatic BRCA1/2 test among January 2016 to August 2020. Successively, we 
analyzed 192 patients with a strong personal and/or family history to BC and/or OC resulted 
BRCA1/2 negative with a multi-gene panel testing. 
The medical personal history of patients was retraced during genetic counselling in presence 
of a multidisciplinary team constituted by an oncologist, a geneticist and a psychologist. All 
patients provided an informed consent and information regarding personal and familial 
history of cancer, family geographical origin, age of cancer diagnosis, histological tumor 
subtype, molecular phenotype and disease stages (I–IV), were anonymously recorded. Data 
concerning histological type and tumor diagnosis were reported by medical pathology in 
diagnostic core biopsies or tumor resections.  
To breast cancers, relying on histological grade and biomarker expression, tumors were 
divided as  luminal A-like (LA= ER/PR+ and HER2-, histological grade 1 or 2), luminal B-like 
(LB= ER/PR+ and HER2+, or ER/PR+, HER2-, and grade 3), HER2 enriched and  triple 
negative (ER-, PR- and HER2-) [122].  
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After genetic counselling and Hereditary Breast and Ovarian Cancer syndrome (HBOC) risk 
estimation, the patients were evaluated for both germline and somatic BRCA1/2 genetic 
screening in OC patients and germline test in BC patients based on criteria established by 
the Italian Association of Medical Oncology (AIOM) also reported in section 1.1.3 [123].  
 
2.2 Sample Collection and Next-Generation  
     Sequencing Analysis 
 
Peripheral blood was collected from HBOC patients. In addition, to OC patients, biopsy 
Formalin-Fixed Paraffin-Embedded (FFPE) ovarian neoplastic tissue samples had been 
available as exploratory biopsies or neoplastic tissue removed with surgery. Tissues 
samples were sectioned at 4 μm with >20% of malignant origin by the laboratory of 
pathological anatomy section of the same hospital agency. Genomic DNA was isolated from 
the peripheral blood using the DNeasy® Blood Kit (QIAGEN), while the isolation of DNA 
from FFPE tissue had been performed by QIAamp® DNA FFPE Tissue Kit (QIAGEN). 
Genomic DNA was quantified by Qubit®3.0 fluorometer (Thermofisher Scientific) and its 
quality was provided by use of 2100 Bioanalyzer (Agilent Technologies). To conduct the 
BRCA1/2 analysis in germline/somatic samples, we used 4 ng of DNA to prepare the 
barcoded library using BRCA Screen kit (4bases SA) that has allowed to investigate all the 
exons of BRCA1 (NM_007300.3) and BRCA2 (NM_000059.3) genes. This kit consists of 
three multiplex PCR primer pools and we employed 20 ng of DNA for each primer pool to 
multiplex PCR amplification, followed by barcode ligation and purification with Agentcourt 
AMPureXP reagent (Beckman Coulter). Quantity and quality of libraries was assessed by 
Qubit®3.0 fluorometer (Thermofisher Scientific) and Agilent 2100 Bioanalyzer on-chip 
electrophoresis (Agilent Technologies), respectively, as previously described [124]. 
Subsequently, libraries were mixed in an equal concentration and emulsion PCR was 
performed using the Ion OneTouch OT2 System (Thermofisher Scientific) with Ion 520 & Ion 
530 Kit-OT2 (Thermofisher Scientific). At the end, sequencing was performed with Ion 520 
Chip (Thermofisher Scientific) using Ion Torrent S5 (Thermofisher Scientific) instrument. The 
sequencing data was analyzed with two different software Amplicon Suite (SmartSeq s.r.l.) 
and Ion Reporter Software v.5.14 (Thermofisher Scientific).  
To analyze multi-gene panel testing, we used a HEVA SCREEN kit (4bases SA) that has 
allowed to evaluate 22 genes involved in risk of hereditary breast, ovarian and colorectal 
cancer, and other inherited tumor syndromes (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, 
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CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, 
RAD50, RAD51C, RAD51D, STK11, and TP53) with the same method above mentioned.  
The data analysis has been performed with the standardization of sequencing coverage 
depth to minimize the probability of false positive and false negative results. There is 
currently no consensus on the minimum coverage depth and each laboratory must set its 
own parameters. A minimum coverage of 5000x and 500x to sample coverage has been 
considered as somatic and germline cut off analysis respectively.  
 
2.3 Sanger sequencing 
 
Pathogenic variants and likely pathogenic variants identified with NGS were confirmed with 
Sanger sequencing using SeqStudio (Thermofisher Scientific) with BigDye Therminator 3.1 
Cycle Sequencing Kit (Life Technologies) 
 
2.3 CNV Analysis by Multiplex Ligation-Dependent  
     Probe Amplification Analysis (MLPA) 
 
The presence of Large Genomic Rearrangements (LGR) was furthermore tested by 
Multiplex ligation-dependent probe amplification (MLPA), by SALSA MLPA probemix P002-
C2 for BRCA1 gene and SALSA MLPA probemix P090 for BRCA2 gene according to the 
manufacturer’s instructions (MRC–Holland, Amsterdam, the Netherlands). Probe 
amplification products were investigated by capillary electrophoresis using ABI 3130 
Genetic Analyzer (Applied Biosystems). Results were evaluated by GeneMapperTM 
Software Version 3.5 (Applied Biosystems) to determine peak heights and areas and 
fragment sizes in base pairs (bp), as described previously [125]. Positive results were 
validated with a second analysis using the same kit on another blood sample. 
 
2.3 Genetic Variant Classification 
 
The detected genetic variants were classified based on criteria developed by Evidence-
based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium 
(https://enigmaconsortium.org/) and divided into five classes: benign (class I), likely benign 
(class II), variant of uncertain significance (VUS, class III), likely pathogenic (class IV), and 
pathogenic (class V) as previously reported in section 1.1.3. Several databases were used 
to identification and classification of genetic variants, such as ClinVar, BRCA Exchange, 
LOVD and Varsome.  
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The variant detected were named according to the recommendations for the description of 
sequence variants offered by the Human Genome Variation Society (HGVS) that is 
approved by, Human Variome Project (HVP), and the Human Genome Organization 
(HUGO) [126]. 
2.4 Statistical analysis 
 
Clinico-pathological variables and prevalence of PVs/LPVs were evaluated for each 
subgroup of patients. The comparison between subgroups was made with Fisher’s Exact 
test. P-values < 0.05 were considered significant. Statistical analyzes were conducted using 



















3.1 BRCA1/2 analysis in BC patients 
 
Between January 1, 2016, and February 28, 2020, 531 BC patients who met eligibility criteria 
for BRCA1/2 gene testing, were included in the retrospective study. According to national 
guidelines, the genetic counselling and the BRCA1/2 mutational screening were offered at 
the “Regional Center for the prevention, diagnosis and treatment of rare and heredo-familial 
tumors of adults” of the Section of Medical Oncology of the University Hospital Policlinico 
“P. Giaccone” of Palermo. 
Analysis was conducted after an appropriate informed consent signed. 
Molecular subtypes identified were 125 (23.5%) Luminal A (LA), 223 (42%) Luminal B (LB), 
29 (5.5%) HER2-enriched (HER2E), and 154 (29%) TNBC. 
Among the 531 BC, 83 (15.6%) were positive for BRCA1/2 PV. In particular, 39 (47%) 
showed a PVs in BRCA1 gene, 43 (51.8%) were BRCA2-positive, and 1 patient (1.2%) 
revealed a double heterozygosity for BRCA1 and BRCA2 genes. Between BC with PVs in 
BRCA1 gene, 28 (71.9%) showed TNBC, 10 (25.6%) a LB tumor, 1 (2.5%) HER2E and none 
LA. Between BC BRCA2-positive, 29 (67.5%) had LB, 6 (13.9%) TNBC, 6 (13.9%) LA and 
2 (4.7%) HER2E. Tumors of the BRCA1 carriers were most frequently TNBCs (p=0.0001), 
while in BRCA2 carriers were predominantly LB/HER2-negative (p=0.0014) (Table 2). 
In this study, the typology and gene location of germline BRCA1/2 PVs in triple-negative vs. 
luminal-like breast cancers to identify potential association between specific PVs and tumor 
phenotype was also evaluated. From data analysis, it was seen that 83 patients showed 45 
PVs in BRCA1/2 genes; 23 were in TNBC patients, of which 18 in BRCA1 gene and 5 in 
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BRCA2 gene. Regarding the other molecular subtypes, 33 PVs in BRCA1/2 genes in 
luminal-like BCs were observed, 8 in BRCA1 and 25 in BRCA2, whereas 3 PVs was 
observed in HER2E BCs divided in 1 in BRCA1 and 2 in BRCA2 (Table 3 and 4). 
In TNBC patients the most frequent PV was c.514del in BRCA1 gene, showed in 5 probands. 
This PV determine the deletion of one Cytosine causing a frameshift and a creation of 
premature stop codon at position 62 of new reading frame producing a BRCA1 protein 
truncated or absent [127]. The second most common PV in BRCA1-positive TNBC patients 
was the c.3904G>T, showed in 3 families. This PV cause a substitution of Guanine in 
Thymine in exon 11 at codon 1302 determining a premature stop codon and a BRCA1 
protein truncated. Based on this data, no association between PVs in BRCA1/2 genes and 
TNBC was observed in Sicilian population because the PVs detected in both genes showed 
a low prevalence.  
Regarding the gene localization of BRCA1 PVs identified in TNBC patients, three 
hypothetical cluster regions were recognized in BRCA1 gene that include RING domain, 
exon11 region and BRCT domain. Specifically, 10 (55.5%) out of 18 BRCA1 PVs were 
reported in region of exon 11, 4 in BRCT domain and 2 in RING domain. About type 
mutation, 11/18 were frameshift mutation, 3 nonsense, 3 missense and 1 was a Large 
Genomic Rearrangement (LGR) involving exons 1 to 15 (figure 3). 
In luminal-like BC patients, the most common founded PVs in BRCA1/2 genes was 
c.1238del in BRCA2 gene in 8 probands with LB breast cancer. This PV cause a deletion of 
a Thymine and a premature stop codon with a loss of protein function. Furthermore, most 
variants present in luminal-like BC patients arise in BRCA2 gene, for example LA patients 
not showed PVs in BRCA1 gene. Like as TNBC patients, also in luminal-like BC patients 
none PV in BRCA1/2 genes showed a significant prevalence without significant association 
between BRCA1/2 variants and luminal-like BC patients. 
The gene localization of BRCA1 PVs in luminal-like BC patients follows the equal distribution 
in the same three cluster regions. To BRCA2 gene, PVs were localized in three supposed 
cluster region that include at N-terminus the PALB2 binding, BRC repeats (in the exon 11), 
and DNA binding helical domain. Regarding the mutation type, the majority (9) were 








3.1.1 Association among BRCA1/2 PVs and 
         clinical factors in BC patients 
 
In TNBC group, BRCA-positive patients were mainly in premenopausal at BC diagnosis with 
mean age of 43.7 (median 43). In terms of mean age between BRCA1 and BRCA2 PV 
carriers, a statistically significant difference was noticed. The mean age for BRCA1 carriers 
was 41.7 years (median: 42; range: 28–58 years) versus 52.8 years (median 52.5; range: 
42–62 years) for BRCA2 PV carriers, and versus 48.2 years (median 48; range: 30-70 years) 
in subjects with no BRCA1/2 PVs. Based on this data, patients with TNBC BRCA1-positive 
developed a BC 6.45 years before non-carrier (p<0.001) and 11.1 years previous than 
BRCA2 PV carriers (p<0.001) (Figure 5A). According to the age group, the prevalence of 
PVs was 35.3% (12/34) in age group ≤ 40 years, 47.1% (16/34) in age range of 41-50 years, 
14.7% (5/34) in range 51-60 years and 2.9% (1/34) in patients with age >60 years (Table 
5). 
Patients BRCA-positive with luminal-like tumors had a mean age at BC diagnosis of 43.75 
years (median 40), specifically 39.1 years (median: 36.5; range: 31-55 years) for BRCA1-
carriers and 45.1 years (median: 41; range: 26-82 years) for BRCA2-carriers. Instead, 
patients without PVs in BRCA1/2 genes had mean age at BC diagnosis of 45.7 years (21-
84 years; median: 44.5). Patients BRCA1-positive with luminal-like developed BC 6.6 years 
before non-carrier (p= 0.0538), and 6 years earlier than BRCA2 PVs carriers (p=0.78) 
(Figure 5B). By dividing luminal-like BC patient in age group, prevalence of PVs was 58% 
(27/46) in age group ≤ 40 years, 20% (9/46) in age range of 41-50 years, 13% (6/46) in 
range 51-60 years, and 9% (4/46) in patients with age >60 years (Table 5). 
Clinico-pathological differences between BRCA PVs carriers and non-carriers BC patients 
were observed. In luminal-like BC patients, BRCA-carriers were frequently associated to 
lower ER (p=0.001) and PR expression (p = 0.007) and were more often HER2-negative 
(p=0.048). Moreover, in this subgroup, BRCA carriers showed a high proliferation rate 
(Ki67%; p=<0.001) and upper histological grade (Grade III vs. I/II) than non-carriers 
(p=<0.001). In both analyzed subgroups, BRCA carriers seem to have an axillary nodal 
involvement than non-carriers (p=0.002 and p=0.016, respectively), while no statistically 
significant difference was showed in tumor size (T) (p=0.802 and p=0.92, respectively).  
Ductal histotype was the principal histotype in both subgroups, without substantial 
differences among BRCA-carriers and non-carriers (p=0.337 and p=0.7, respectively). 
Contralateral BC was present in 96 (19.1%) patients; in particular 5/34 (14.7%) were TNBC 
BRCA1/2 positive, 13/46 (28.2%) were luminal-like BRCA1/2 positive and 78/422 (18.4%) 
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were BRCA1/2 negative. In 78 contralateral BC BRCA1/2-negative, 12/120 (10%) were 
TNBC and 66 (21.8%) out of 302 were Luminal-like. In BRCA1/2-positive TNBC patients, 
contralateral BC were diagnosed at earlier age than BRCA1/2-negative (50vs56 years; 
p=0.033). Whereas in Luminal-like the difference was lower (52 vs 53 years).  
Median time between the first and second tumor was 10 years in patients with TNBC BRCA-
positive and 6.5 years in BRCA-negative (p=0.389). In Luminal-like patients, the median 
time of contralateral BC was shorter in BRCA-positive (4 years) and BRCA-negative patients 
(3 years) (p=0.465). In general, the median time of onset of bilateral tumors was lower in 
luminal-like than TNBC patients. 
 
3.2 BRCA1/2 analysis in OC patients 
 
A total of 345 patients affected by OC was retrospectively analyzed; 85 of which (24.6%) 
were resulted altered in BRCA1/2 genes. In particular, 56 (65.9%) were resulted BRCA1-
positive and 29 (34.1%) showed a PVs/LPVs in BRCA2 gene. The distribution of these 
variants was reported in Table 6. 
The most frequent PV identified in 8 probands (9.2%) was c.4964_4982del in BRCA1 gene. 
This variant is characterized by a deletion of 19 nucleotides that produces a frameshift with 
a premature stop codon and the loss of normal protein function. In our recently published 
work, this variant resulted the most widespread PV in the Sicilian population [7]. Indeed, 
today is considered a potential Sicilian founder mutation [128]. The second most recurrent 
variant detected was c.514del in BRCA1 gene highlighted in 5 families (5.7%). Interestingly, 
a variant named c.4963T>G in BRCA1 gene was noted in 3 (3.5%) different patients. Protein 
change causes a substitution of Serine with Alanine. Since Serine in position 1655 is a highly 
conserved residue, this variant is probably considered as Pathogenic. 
In BRCA2 gene, we have not noted a most recurrent variant. In fact, only 6 different variants 
were detected in no more than 2 (2.3%) patients.  
A variant type in BRCA1/2 genes was also evaluated. In fact, it was possible to identify 48 
(56.4%) frameshift mutations (fs), 19 (22.3%) NonSense (NS), 11 (12.9%) Missense (M), 6 
(7%) Intronic Variants Sequencing (IVS) and 1 (1.2%) Synonymous. In details, in BRCA1 
gene, we highlighted 33 (58.9%) variants of frameshift nature, 11 (19.6%) NonSense, 9 
(16%) Missense and 3 (5.3%) IVS. Instead, in BRCA2 gene was identified 15 (51.7%) 
frameshift mutations, 8 (27.7%) NonSense, 3 (10.3%) IVS, 2 (6.9%) Missense and 1 (3.4%) 
synonymous PV (Figure 6). 
Among 116 performed somatic tests, 15 (12.9%) were resulted BRCA1/2 positive. In 
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particular, 10 PVs were revealed in BRCA1 and 5 in BRCA2 genes. However, any 
correlation noteworthy was not found about frequency distribution. 
 
3.2.1 Association among patients BRCA1/2- positive 
        and clinical factors in OC patients 
 
Between OC patients BRCA1/2-carriers and no-carriers, the analysis reveal a statistically 
significant difference in age at diagnosis (median: 56vs58; mean: 57.9vs58.6; range: 24-
86vs37-81; p=0.02). According to the age group, the prevalence of patients in both analyzed 
groups was in the 51-60 range, with 36.5% and 38.5% respectively, and in the 61-70 range 
(25.8%vs25.4%). However, no statistically significant difference was noted.  
As expected, the most recurrent cancer site either in BRCA1/2 wt and BRCA1/2-carriers 
was ovarian carcinoma with 82.3% and 63.5% of patients respectively. Noteworthy, the 
34.1% of patients with bilateral ovarian carcinoma showed a PVs/LPVs in BRCA1/2 genes 
versus only 8% of patients without variants (p<0.00001). Moreover, a little difference was 
noted in patients with primary peritoneal carcinoma of which 9.3% resulted BRCA1/2 wt and 
only 2.4% were BRCA1/2-carriers. 
Another important and statistically significant difference in patients with alteration in BRCA 
genes was highlighted. The 57.7% of these subjects showed a FIGO stage III versus 13.8% 
of patients without alterations (p=0.02), although 73.8% of these last patients had the FIGO 
stage unknown. 
Regarding the histological subtypes, most patients presented a high-grade serous 
carcinoma (HGSC) either in BRCA1/2-carriers subgroup (80%) and in group of BRCA-no 
carriers (68.5%), as reported in literature. The second most frequent subtype in both 
analyzed group was the Endometrioid carcinoma, represented in 7.1% of BRCA-carriers 
and in 9.2% of no-carriers. 
An important obtained result was that the 17.6% of BRCA1/2 carriers showed a personal 
BC history before OC, while only 6.5% of patients BRCA1/2 no-carriers showed a previous 
personal BC history (p=0.007). In particular, 9/29 (31%) patients with BRCA2 PVs/LPVs had 
a prior BC history while only 6/56 (10.7%) BRCA1-carriers had a BC history before the OC. 







3.3 Detection of Germline Pathogenic Variants in 
      Cancer Susceptibility Genes by Multi-Gene Panel 
      Testing 
 
After BRCA1/2 testing, 192 patients (165 of whom affected by BC and 27 affected by OC) 
were resulted BRCA1/2 negative with a strong personal and/or family history of breast and 
ovarian cancer. These subjects were selected to multi-gene panel testing analysis, based 
on indication of the multidisciplinary team. Obtained data revealed that 28 (14.6%) BC and 
OC patients showed PVs/LPVs in genes no-BRCA ( Figure 7). 
In the165 BC patients (160 women and 5 men) analyzed with multi-gene panel approach, 
24 (14.5%) showed PVs/LPVs in other BC susceptibility gene (no-BRCA) (Table 8). 
Specifically, 6 (25%) probands have been shown to harbour PVs in MUTYH 
(NM_001048171) gene, 4 (16.6%) probands in CHEK2 (NM_001005735) gene, 3 (12.5%) 
probands in RAD51C (NM_002876) and in PMS2 (NM_000535) genes respectively, 2 
(8.3%) patients presented PVs in PALB2 (NM_024675) and ATM (NM_000051) genes 
respectively. In addition, 1 (4.2%) PVs in RAD50 (NM_005732), PTEN (NM_000314), MSH2 
(NM_000251) and CDH1 (NM_004360) genes were presents in singular patients (Figure 8). 
Conducted analysis revealed that among 24 patients (no-BRCA), 11 (45.8%) were affected 
by Bilateral Breast Cancer (BBC). In detail, these 11 PVs were divided in this manner: 2 in 
CHEK2, 2 in PALB2, 2 in ATM, 2 in RAD51C, 2 in MUTYH and 1 in MSH2 genes.  
The most frequent PV in the retrospective analysis was a missense mutation in MUTYH 
gene in heterozygous condition named c. 1145G>A in 5 probands (20.6%), that is normally 
linked to MUTYH-associated colon polyposis (MAP) syndrome and colorectal cancer [129]. 
In our cohort, this PV was strongly associated with Luminal B and HER2 negative BC.  
The second most recurrent PV was c.1229del in CHEK2 present in 2 (8.3%) individuals 
affected by BBC. This result was according to published data in our precedent work yet [8]. 
In fact, this variant was correlated with BBC and in particular to BC with Luminal A/B 
phenotype, estrogen receptor positivity >60%, and progesterone receptor positivity between 
20% and 60% [8].  
Another frequent variant was a IVS in CHEK2 gene called c.721+3 A>T, discovered in 2 
(8.3%) patients. The nature of this variant is still to define. In fact, database as ClinVar 
reports it as Conflicting Interpretations of Pathogenicity (CIP), although could be probably 
considered a PV being a splice site mutation.  
Despite PALB2 has been shown to be one of the most frequently altered gene in BC 
patients, in our analysis only two patients (8.3%) exhibited an alteration in this gene. 
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However, both of these patients showed a BBC whereby a correlation between this PV and 
BBC could be hypothesize.  
Among 27 OC patients, 4 (14.9%) were showed a PVs/LPVs in other genes no-BRCA (Table 
8). In particular, 2 patients (50%) showed a PV in MUTYH gene, and 1 PV in ATM and PMS2 
genes were present in two patients (25%) singularly.  
Patients with MUTHY PV presented variant named c.1145G>A in heterozygous condition 
as patients with BC. One patient showed a variant in ATM gene called c.4776+1G>T 
capable of acting as a donor splice site in intron 31 of the ATM gene. Considering in silico 
analysis, this variant has been classified as Likely Pathogenic because it is expected to 
disrupt RNA splicing and probably to delineate an absent protein product. 
Last patient harbouring a PV had a c.2249G>A in PMS2 gene in homozygous condition. 
This variant involves a substitution of glycine, highly conserved residue, with aspartic acid 
at codon 750 and has been noted in patients with constitutional mismatch repair deficiency 
syndrome. 
 
3.3.1 Comparison between BRCA1/2 PVs/LPVs, Multi- 
         Gene Panel Testing, all wild-type and clinical 
         factors 
 
The median age at diagnosis of BC patients with PVs/LPVs in gene over BRCA1/2 was 
lower than BRCA1/2 positive and all wild-type (wt) (median age: 32vs41 p=0.8; 32vs44 
p=0.9;) with a mean age that conversely was higher than other groups (mean age: 
45.6vs42.6vs44.5 respectively). Most patients with PVs/LPVs either on BRCA1/2 and in 
other genes had an age at diagnosis ≤40 years.  
Significant clinico-pathological differences among three subgroups of BC were observed 
(Table 9). Patients with alterations in BRCA1/2 (86.8%) and without any alterations (77.4%) 
often presented a ductal BC rather than patients with alteration in genes over BRCA1/2 
(54.2%).  
Interestingly, only 3 patients (12.5%) with PVs/LPVs in the panel were TNBC compared to 
34 patients (40.9%; p=0.12) with BRCA1/2 and 149 (25.3%; p<0.00001) without alterations 
in genes analyzed.  
Another important observation was that PVs carriers in other genes did not have a high 
proliferation rate and a higher histological grade than BRCA1/2 carrier (p=0.003) and-non 
carrier (p=0.24). Furthermore, an involvement of axillary nodal did not presented than other 
two groups (p=0.07; p=0.002). 
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As mentioned above, 11 patients resulted altered with multi-gene panel analysis had a BBC. 
This result was statistically significant either compared to BRCA1/2 carriers (p=0.04) and to 
all wt (p=0.008). 
Comparing only patients analyzed with multi-gene panel, no correlation statistically 
significant was showed between mutated and wt. However, noteworthy result was that 
patients mutated had a median age at diagnosis considerably lower than wt (median: 32 vs 
43.5 years; p=0.24). Regarding patients with BBC, the median time between 1st and 2nd 
tumor was longer in mutated than patients without alteration. 
Considering patients affected by OC, the median age at diagnosis was similar between 
subjects with PVs/LPVs in other genes over BRCA1/2 and wt for multi-gene panel (52.5vs52  
years, respectively). A comparison among OC patients with PVs/LPVs in BRCA1/2 genes, 
multi-gene panel mutated and all wt was conducted. We observed that women with 
PVs/LPVs in genes over BRCA1/2 tends to develop OC before than other two groups 
(median: 52.5vs56vs58 years). Dividing in age groups, women characterised by an 
alteration in genes over BRCA1/2 genes were distributed in all different groups. In other two 
analyzed groups, the most represented zones were the patients over the sixth decade of 
life.  
Based on tumors characteristics, patients mutated in multi-gene panel showed an ovarian 
carcinoma with high-grade serous carcinoma as histological subtype, and in the 50% of 
cases a FIGO stage III. Same results were observed in other two groups, though in all wt 
subgroup the majority of patients had a FIGO stage unknown.  
At the end, BRCA1/2-carriers group and also the group of patients with PVs/LPVs in genes 
over BRCA1/2 the 75% of patients showed a personal history of BC or other cancer. Clinico-
pathological characteristic were reported in Table 10. 
Obviously, these results are not considered statistically significant due to the low number of 
















HBOC syndrome is an autosomal dominant inherited disorder that represent about 5–7% of 
all breast cancer (BC) cases and 10-15% of all ovarian cancer (OC) cases [2]. NCCN 
established clinical guidelines to distinguish HBOC patients [3] that had an increased risk to 
develop additional cancer like as pancreatic cancer, prostate cancer, and melanoma. 
BC and OC are heterogeneous diseases with the involvement of different environmental 
and genetic risk factors. This heterogeneous nature is underlined from recent advances in 
genetic and genomic fields. Indeed, in the last few years genetic test request to integrate 
the information about prevention, surveillance and treatment decision making. 
BRCA1/2 are main genes involved in inherited predisposition to HBOC syndrome. In 
particular, the presence of PVs/LPVs in these genes increase the risk to develop breast 
cancer for 50–85% BRCA1/2 carriers and to develop ovarian cancer for 15–45% and 10–
20% to BRCA1 and BRCA2 carriers respectively. However, several patients result negative 
for BRCA1/2 analysis and further genetic testing are need using panel with many other 
genes. In fact, HBOC syndrome could be associated with germline PVs/LPVs in several 
high-risk genes such as CDH1, PALB2, PTEN, STK11, TP53, or moderate-risk genes like 
ATM, CHEK2, BARD1, BRIP1, RAD51C, RAD51D. For these reasons, to date the use of 
multi-gene panel testing containing several susceptibility genes is becoming progressively 
regular in clinical practice [8]. This is possible also thanks to the progress obtained by NGS 
technology which revolutionized the clinical approach to genetic testing. Recently, several 
studies showed that a considerable number of PVs/LPVs can be missed if syndromes like 
as HBOC, Cowden syndrome, Li–Fraumeni syndrome, Lynch syndrome are tested 
independently. Therefore, a multi-gene panel testing that covering all these syndromes were 
applied [130].  
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In this work, we have retrospectively analyzed 531 BC patients for germline PVs in BRCA1/2 
genes according to national guidelines. We revealed 83 patients with BRCA1/2 PVs. These 
variants resulted more frequent in TNBC subgroup (22.1%), followed by Luminal B (18%), 
HER2E (10.2%) and Luminal A (4.8%). Analysis allowed to reinforce the strong association 
between TNBC and BRCA1 PVs and between Luminal B BC and BRCA2 PVs. In our cohort, 
BC BRCA-positive arise in younger women. Patients BRCA1-positive developed BC before 
than BRCA2 carriers and non-carriers, moreover TNBC BRCA1-carriers had a greater 
difference in age at diagnosis than TNBC BRCA2-carriers.  
Based on prognostic factors, patients BRCA1/2 carriers showed a greater percentage of 
Ki67-positive cells, had a high histological grade and an axillary nodal involvement. Patients 
with Luminal-like BC and a PVs in BRCA1/2 showed a lower expression of ER, PR and 
HER2. 
Furthermore, differences in presence of bilateral tumors in BRCA1/2 carriers than no-
carriers were observed.  
In Luminal-like subgroup with BRCA1/2 PVs, contralateral BC was more common and 
characterised by lower median time to second tumor development than TNBC and BRCA1/2 
no-carriers.  
Regarding variant type, most BRCA1 PVs in TNBC and PVs in BRCA2 were frameshift 
mutations. In Luminal-like subtype we revealed an elevated percentage of intronic 
pathogenic variants in BRCA2 gene. Based on distribution of PVs in BRCA1/2 genes, we 
have noticed that two variants were probably associated with TNBC and Luminal-like 
respectively. In particular, BRCA1-c.514del was presented with high frequency in 5 families 
with TNBC and only 2 families with LB tumors. Specifically, this variant was associated at 
TNBC diagnosed at younger age characterized by poor prognostic factors as Ki67 
percentage and nuclear grade. Furthermore, considering that this PVs is infrequently 
presented in Italy or in World, could be further studied for a possible founder effect for the 
Sicilian population. 
In BRCA2 gene, variant named c.1238del was noted in 8 families with LB tumors and in 
none TNBC families. Specifically, this PVs was associated at patients who carried a high 
proportion of bilateral breast tumors [8] that were HER2-negative with higher ER expression 
(range 70-95%). 
Moreover, we tried to identify a possible genotype/phenotype correlation based on PVs site 
correlated to TNBC or Luminal-like risk in our cohort. We have noted that most PVs revealed 
in TNBC and Luminal-like BCs were located at exon 11 of both genes, that correspond to 
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majority of coding sequence in both genes and is considered a “coldspot” to missense PVs. 
In addition, we showed that other two regions as RING domain and BRCT domain could be 
involved in TNBC risk. However, our data do not allow to describe new regions other than 
OOCRs and BCCRs already known in literature. The heterogeneous distribution of PVs and 
their low frequency in TNBC patients could reflect the genetic heterogeneity of Sicilian 
population, maybe determined by the colonization by many and different peoples during 
history. 
Knowledge about mutational background underlying the phenotype of each tumor can have 
not only prognostic but also therapeutic implications. 
Systemic therapies are usually chosen through few well-established biomarkers of 
therapeutic response as ER, PR expression and HER2 overexpression.  
In TNBC, that do not present these biomarkers, chemotherapy is the standard treatment 
and typically involves the use of anthracycline and taxane, thought in BRCA-positive 
platinum-based agents and PARP inhibitors showed a peculiar efficacy.  
We hypothesized that the genetic heterogeneity could be present also in TNBC BRCA1/2-
related, defining the phenotype of BCs associated with PVs. This could make them possible 
candidates to different treatment choices.  
In our analysis group, patients with c.514del in BRCA1 gene exhibited a less 
chemosensitivity than those harbouring c.3904G>T and c.5266dup both in BRCA1 gene, 
this analysis, however, shows some potential limitations. Our research suggests that 
chemosensitivity in TNBC patients may largely vary in the same molecular phenotype of the 
tumor and should be interpreted carefully due to the limited number of patients analyzed.  
Analysis on 345 patients with OC revealed that 85 (24.6%) presented alterations in BRCA1/2 
genes. In detail, we showed that the majority were BRCA1-positive (65.9%) and 34.1% 
showed a PVs/LPVs in BRCA2 gene. About of distribution on both genes, we did not note a 
specific cluster region. However, in BRCA1 gene, we registered a high prevalence of two 
possible Sicilian founder mutation named c.4964_4982del and c.514del described in 8 and 
5 probands respectively. An important observation was the presence of variant called 
c.4963T>G in BRCA1 gene revealed in 3 probands, and that its possible considered as 
pathogenic because cause a substitution of one highly conserved Serine residue in position 
1655 with an Alanine. 
In BRCA2 gene, we have not observed a prominent variant among OC patients. By focusing 
on BRCA1/2 variant type, we noted a predominance of frameshift mutations either in BRCA1 
and in BRCA2 gene which remain the most common type of variants noted. 
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About of clinicopathological characteristics of OC patients, we observe a statistically 
significant difference based on median age at diagnosis that was 56 versus 58 years in 
BRCA1/2 carriers and no-carriers respectively (p=0.02). In our analysis group, like as in 
literature, OC develops in the sixth decade of life indeed the most prevalence of patients 
arises in 51-60 years and 61-70 years zones. 
Regarding cancer site, the most prevalent was ovarian carcinoma in 82.3% and 63.5% of 
BRCA1/2 carriers and no-carriers respectively. An important result observed in this study 
was that the 34.1% of patients with bilateral ovarian carcinoma showed a PVs/LPVs in 
BRCA1/2 genes, while only 8% of patients without variants showed a bilateral ovarian 
carcinoma (p<0.00001). Moreover, the 57.8% of BRCA1/2 patients showed a FIGO stage 
III in comparison of 13.8% without alteration (p=0.02). At the end, the 17.6% of BRCA1/2 
carriers showed a personal BC history before OC, while only 6.5% of patients BRCA1/2 no-
carriers showed a previous personal BC history (p=0.007). 
Successively, we investigated 192 HBOC patients with strong personal and/or family history 
resulted BRCA1/2 negative selected by the consulting of multidisciplinary team. Analysis 
were conducted by multi-gene panel testing to understand if these patients harboured a 
PVs/LPVs in high- and moderate-risk genes involved in hereditary cancer syndrome. We 
revealed 28 (14.6%) patients with a PVs/LPVs in high- and moderate-risk genes. In 
particular, we analyzed 165 BC patients of which 24 (14.5%) with a PVs/LPVs and 27 OC 
patients of which 4 (14.9%) presented a PVs/LPVs in genes beyond BRCA1/2. These results 
are consistent with the literature review. 
Interestingly, patients that presented PVs/LPVs in genes over BRCA1/2 develop a BC or 
OC before patients with BRCA1/2 PVs/LPVs (median: 50 vs 43 years)  
In particular, we observed that variant named c.1145G>A in MUTYH gene were presented 
in 7 patients analyzed, 5 BC and 2 OC. In our study, this variant was reported in 
heterozygous condition and it is located in the 8-oxo-G binding site within the Nudix domain 
[131]. In silico studies supports a damaging impact on protein product, therefore it is 
classified as pathogenic. In literature has been noted that in homozygous and compound 
heterozygous state, it is linked to MUTYH-associated colon polyposis (MAP) syndrome and 
colorectal cancer.  
In BC patients, a possible correlation between BBC and variant c.1229del, also known 
c.1100del, in CHEK2 gene was noted. This variant was present in two patients, and both 
had a BBC and were Luminal B and HER2 negative. This correlation was also observed in 
our recently published work, where considered PV was showed in 5 patients with BBC [8]. 
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Furthermore, 11 out of 24 (45.8%) BBC patients analyzed in this study revealed a PVs/LPVs 
in genes beyond BRCA1/2. Besides c.1229del in CHEK2 gene, we noted alterations in 6 
different genes as PALB2, ATM, RAD51C, MUTYH and MSH2; therefore, it is possible 
hypothesize a strongly association between BBC and genes involved in HR pathway. 
By focusing on 27 OC patients analyzed with multi-gene panel approach, we have noted 
that 4 (14.8%) patients have PVs/LPVs in genes over BRCA1/2 distributed in three different 
genes as MUTYH, ATM and PMS2. Comparing baseline and clinical-pathological 
characteristic, we did not note an important and statistically significant difference among 
three analyzed group probably because the number of patients examined was low. 
Therefore, a future prospective will be to implement this study by increasing collected data.  
Investigating baseline and clinical-pathological characteristic of BC patients studied by multi-
gene panel, our analysis revealed that patients with PVs/LPVs in genes no-BRCA develop 
a BC before than BRCA-carriers and all wt with a median age at diagnosis of 32 years vs 
41 and 44 years respectively. Carriers of PVs/LPVs in genes over BRCA1/2 had a reduced 
probability of developing a TNBC in comparison to BRCA-carriers and all wt which instead 
were often luminal-like. In relation at these results, subjects with PVs/LPVs in other genes 
over BRCA1/2 had a tumor with a lower proliferation rate, a lower nuclear grade and did not 
had an involvement of axillary nodal assuming that these patients could be develop a BC 
less aggressive. In group of no-BRCA carriers, we noted a prevalence of BBC (45.8%) than 
BRCA1/2 (22.9%) carrier and all wt patients (20.5%), tending to develop a 1st and 2nd BC 
later than other groups with a median time between two tumors much longer than all wt and 
similar than BRCA1/2-carriers. 
In conclusion, in this study we highlight that BRCA1-related tumors have frequently a profile 
which seem like the TNBC subtype, while BRCA2-related tumors have a profile similar to 
luminal-like breast cancers, specifically the luminal B tumor subtypes. Moreover, the 
pathogenic variants discovered in TNBC patients were not widely overlapping with those 
detected in Luminal-like tumors, although no evident association between specific BRCA1/2 
PVs and TNBC or luminal-like tumors was noted. 
On 85 OC patients with PVs/LPVs in BRCA1/2 genes, we have found a high prevalence of 
two probably Sicilian founder mutations both in BRCA1 gene, c.4964_4982del and c.514del 
in 8 probands and in 5 probands respectively. By focusing on baseline clinical characteristic, 
we observe that the 34.1% of patients with bilateral ovarian carcinoma showed a PVs/LPVs 




Regarding the 192 patients with a strong personal and/or family history of BC and/or OC 
resulted BRCA1/2 negative analyzed with multi-gene panel testing, the data showed that 
14.6% of these patients presented PVs/LPVs in genes over BRCA1/2. 
These findings highlighted the importance of multi-gene panel testing, which should be 
extended to all patients with a strong personal and/or family history of BC and/or OC who 
are resulted BRCA1/2-negative, with the aim to offer specific risk-reducing measures and 























































Figure 1. Synthetic lethality mechanisms. When a single-strand breaks occurs, the repair is 
completed by BER, NER and MMR. If BER is compromised, through the inhibition of PARP, 
single strand breaks become double strand breaks. In patients with HRD, such as a BRCA-
carriers, this damage causes the cancer cell death by activation of NHEJ. Toss A, Cortesi L 
(2013) Molecular Mechanisms of PARP Inhibitors in BRCA-related Ovarian Cancer. J Cancer 




















Table 2. BRCA1/2 PV detection rate in Luminal A, Luminal B, HER2-enriched and TNBC patients. 
 Total BRCA1 BRCA2 
DH BRCA1-
BRCA2 
No PVs p value * 
Luminal A 125 0 (0%) 6 (4.8%) 0 (0%) 119 (95.2%) p=0.213 
Luminal B 223 10 (4.5%) 29 (13%) 1 (0.5%) 183 (82%) p= 0.0014 
HER2E 29 1 (3.4%) 2 (6.8%) 0 (0%) 26 (89.8%) p=1.00 
TNBC 154 28 (18.2%) 6 (3.9%) 0 (0%) 120 (77.9%) p= 0.0001 
*Comparison BRCA1 PVs vs BRCA2 PVs vs BRCA1/2 wt. DH= Double Heterozygosity; HER2E=Her2-enriched; TNBC=Triple Negative 
Breast Cancer 
  
Figure 2. Molecular mechanisms of the DNA damage response Roy R, Chun J, Powell 
SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat 















BRCA1 Deletion c.514del p.Gln172fs 5 (14.5%) 
BRCA1 SNV c.3904G>T p.Glu1302Ter 3 (9.1%) 




BRCA1 Deletion c.4964_4982del p.Ser1655fs 2 (6%) 
BRCA1 SNV c.3400G>T p.Glu1134Ter 2 (6%) 
BRCA1 Deletion c.798_799del p.Ser267fs 1 (2.9%) 




BRCA1 Deletion c.3228_3229del p.Gly1077fs 1 (2.9%) 
BRCA1 Deletion c.1531del / 1 (2.9%) 
BRCA1 Deletion c.5030_5033del p.Thr1677fs 1 (2.9%) 
BRCA1 Duplication c.66dupA p.Glu23Argfs 1 (2.9%) 
BRCA1 SNV c.5123C>A p.Ala1708Glu 1 (2.9%) 
BRCA1 Deletion c.3266del p.Leu1089fs 1 (2.9%) 




BRCA1 Deletion c.882del p.Asp295fs 1 (2.9%) 
BRCA1 SNV c.2722G>T p.Glu908Ter 1 (2.9%) 
BRCA1 Deletion c.66_67del p.Glu23fs 1 (2.9%) 
BRCA1 LGR c.-232_4675del / 1 (2.9%) 
BRCA2 Deletion c.5851_5854del p.Ser1951fs 2 (6%) 
BRCA2 SNV c.8954-15T>G / 1 (2.9%) 
BRCA2 Deletion c.1238del p.Leu413fs 1 (2.9%) 
BRCA2 Deletion c.9455_9456del p.Glu3152fs 1 (2.9%) 

















BRCA1 Deletion c.4964_4982del p.Ser1655fs 3 (7.5%) 
BRCA1 Deletion c.514del p.Gln172fs 2 (5%) 
BRCA1 SNV c.181T>G* p.Cys61Gly 1 (2.4%) 
BRCA1 SNV c.2722G>T p.Glu908Ter 1 (2.4%) 
BRCA1 SNV c.5096G>A p.Arg1699Gln 1 (2.4%) 
BRCA1 Deletion c.3228_3229del p.Gly1077fs 1 (2.4%) 
BRCA1 Deletion c.66_67del p.Glu23fs 1 (2.4%) 
BRCA1 SNV c.3904G>T p.Glu1302Ter 1 (2.4%) 
BRCA2 Deletion c.1238del p.Leu413fs 8 (19.5%) 
BRCA2 Deletion c.9026_9030del p.Tyr3009fs 2 (5%) 
BRCA2 Deletion c.6082_6086del p.Glu2028fs 2 (5%) 








BRCA2 SNV c.8331+2T>C* / 1 (2.4%) 
BRCA2 SNV c.631G>A p.Val211Ile 1 (2.4%) 
BRCA2 Deletion c.5851_5854del p.Ser1951fs 1 (2.4%) 
BRCA2 SNV c.8754+4A>G / 1 (2.4%) 
BRCA2 SNV c.8632+2T>C / 1 (2.4%) 
BRCA2 SNV c.6124C>T p.Gln2042Ter 1 (2.4%) 
BRCA2 SNV c.7681C>T p.Gln2561Ter 1 (2.4%) 




c.1842dup p.Asn615Terfs 1 (2.4%) 
BRCA2 SNV c.7007G>A p.Arg2336His 1 (2.4%) 




BRCA2 SNV c.396T>A p.Cys132Ter 1 (2.4%) 
BRCA2 Deletion c.5595_5596del p.Phe1866fs 1 (2.4%) 
BRCA2 SNV c.8487+1G>A / 1 (2.4%) 
Luminal A 



































BRCA2 SNV c.8487+1G>A / 
1 
(16.67%) 
BRCA2 SNV c.93G>A p.Trp31Ter 
1 
(16.67%) 






















BRCA2 Deletion c.5073del p.Lys1691fs 1 (33.3%) 
BRCA2 Deletion c.7679-7680del p.Phe2560fs 1 (33.3%) 
Figure 3. Gene location of BRCA1/2 PVs in TNBC patients. Abbreviations: 
BRCT, BRCA1 C-terminus domain; CNV, Copy Number Variant; NLS, Nuclear 
Localization Sequence; OB, Oligonucleotide Binding; PV, Pathogenic Variant; 
































Figure 4. Gene location of BRCA1/2 PVs in luminal-like BC patients. 
Abbreviations: BRCT, BRCA1 C-terminus domain; NLS, Nuclear 
Localization Sequence; OB, Oligonucleotide Binding; PV, Pathogenic 
Variant; SCD, Serine Cluster Domain 
Figure 5. Boxplots showing difference in age at diagnosis among women without BRCA1/2 
PVs versus women with BRCA1 or BRCA2 PV. (a) TNBC subgroup; (b) Luminal-like BC 
subgroup.*WT vs BRCA1 p<0.001; WT vs BRCA2 p=0.26; BRCA1 vs BRCA2 p<0.001; **WT vs 










Luminal-like** *P value **P value 
WT BRCA1/2 WT BRCA1/2   
 
Number of patients (502) 
 
120 (77.9%) 34 (22.1%) 302 (86.8%) 46 (13.2%) - - 














































































































































































































































































































BRCA1 fs c.4964_4982del p.Ser1655fs 8 (9.4%) G 
BRCA1 fs c.514del p.Gln172fs 5 (5.9%) G 
BRCA1 M c.181T>G p.Cys61Gly 4 (4.8%) G 






3 (3.6%) G 
BRCA1 fs c.5266dupC 
p.Gln1756Prof
s 
3 (3.6%) G 
BRCA1 fs c.3226_3227AG p.Gly1077fs 2 (2.3%) G 
BRCA1 fs c.3253dupA 
p.Arg1085Lysf
s 
2 (2.3%) G 
BRCA1 NS c.3904G>T p.Glu1302Ter 2 (2.3%) G 
BRCA1 fs c.115_116TG[1] 
p.Cys39_Asp4
0delinsTer 
2 (2.3%) G 
BRCA1 IVS c.547+2T>A  2 (2.3%) G 




p.Val1234fs 1 (1.2%) G 
BRCA1 NS c.4117G>T p.Glu1373Ter 1 (1.2%) G 
BRCA1 NS c.4327C>T p.Arg1443Ter 2 (2.3%) G 




p.Ala344Ter 1 (1.2%) G 
BRCA1 NS c.5297T>G p.Ile1766Ter 1 (1.2%) G 
BRCA1 NS c.3400G>T p.Glu1134Ter 1 (1.2%) G 
BRCA1 M c.65T>C p.Leu22Ser 1 (1.2%) G 
BRCA1 fs c.984_985insC p.Asn329fs 1 (1.2%) G 
BRCA1 fs c.2269delG p.Val757Phefs 2 (2.3%) S 
BRCA1 NS c.4576G>T p.Glu1526Ter 2 (2.3%) S 
BRCA1 NS c.2059C>T p.Gln687Ter 1 (1.2%) S 
BRCA1 M c.5252G>C p.Arg1751Gln 1 (1.2%) S 
BRCA1 fs c.1674del p.Gly559fs 1 (1.2%) S 
BRCA1 fs c.4891dupA p.Ser1631fs 1 (1.2%) S 
BRCA1 fs c.2292_2293AG 
p.Glu765_Ser
766insTer 
1 (1.2%) S 
BRCA2 M c.631G>A p.Val211Ile 2 (2.3%) G 
BRCA2 fs c.6082_6086del p.Glu2028fs 2 (2.3%) G 
BRCA2 IVS c.1909+1G>A  2 (2.3%) G 
BRCA2 fs c.2808_2811del p.Ala938Profs 2 (2.3%) G 
BRCA2 NS c.3158T>G p.Leu1053Ter 2 (2.3%) G 
BRCA2 fs c.5851_5854del p.Ser1951fs 2 (2.3%) G 
BRCA2 fs c.6323_6324GT 
p.Arg2108_Val
2109insTer 































BRCA2 NS c.5959C>T p.Gln1987Ter 1 (1.2%) G 
BRCA2 fs c.4284dup p.Gln1429fs 1 (1.2%) G 
BRCA2 fs c.5073dupA 
p.Trp1692Metf
s 
1 (1.2%) G 
BRCA2 fs c.5158dupT 
p.Ser1720Phe
fs 
1 (1.2%) G 
BRCA2 fs c.5701_5714del 
p.Ser1900_Gl
u1901insTer 




p.Lys2162fs 1 (1.2%) G 
BRCA2 NS c.7480C>T p.Arg2494Ter 1 (1.2%) G 
BRCA2 IVS c.8331+2T>C  1 (1.2%) G 
BRCA2 fs c.9026_9030del p.Tyr3009fs 1 (1.2%) G 
BRCA2 fs c.9253dupA 
p.Thr3085Asnf
s 
1 (1.2%) G 
BRCA2 NS c.6037A>T p.Lys2013Ter 1 (1.2%) G 
BRCA2 NS c.3883C>T p.Gln1295Ter 1 (1.2%) S 
BRCA2 Syn c.9117G>A p.Pro3039= 1 (1.2%) S 
BRCA2 fs c.3264delT 
p.Gln1089Argf
s 
1 (1.2%) S 
BRCA2 NS c.7366C>T p.Gln2456Ter 1 (1.2%) S 
BRCA2 NS c.7297C>T p.Gln2433Ter 1 (1.2%) S 
Figure 6. Distribution in variant types of PVs/LPVs in BRCA1 and BRCA2 genes. IVS 
(Intonic Variant Sequences) 
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Table 7. Baseline characteristics and clinico-pathological information of OC patients 
 BRCA1/2 wt BRCA1/2 p value 
 
Number of patients: 345 
 
260 (75.4%) 85 (24.6%) / 
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Figure 7. Distribution of PVs/LPVs revealed in 28 BC and OC patients 
analyzed with multi-gene panel testing. cancer patients. The 
OncoPrint, showing the identified PVs/LPVs by heatmap, was obtained by 
the informatic tool Mutation Mapper-cBioPortal for Cancer Genomics. The 








































Breast Cancer patients 
MUTYH M c.1145G>A 
p.Gly382A
sp 
PV 5 (20.6%) 
CHEK2 fs c.1229del p.Thr410fs PV 2 (8.2%) 
CHEK2 IVS c.721+3A>T / CIP/PV 2 (8.2%) 
CDH1 IVS c.2164+2T>C / PV 1 (4.2%) 
MSH2 M c.1045C>G 
p.Pro349A
la 






CIP/PV 1 (4.2%) 
PMS2 M c.137G>T p.Ser46Ile LPV 1 (4.2%) 




/ LPV 1 (4.2%) 
RAD51C NS c.224dup 
p.Tyr75Te
r 
PV 1 (4.2%) 
RAD51C M c.773G>A 
p.Arg258H
is 
LPV 1 (4.2%) 
PTEN M c.284C>A 
p.Pro95Gl
n 
PV 1 (4.2%) 
RAD50 NS c.3598C>T 
p.Arg1200
Ter 
PV 1 (4.2%) 
MUTYH M c.494A>G 
p.Tyr165C
ys 
PV 1 (4.2%) 
PALB2 fs c.758dup p.Ser254fs PV 1 (4.2%) 
PALB2 fs c.1050_1053del p.Thr351fs PV 1 (4.2%) 
ATM M c.8147T>C 
p.Val2716
Ala 






PV 1 (4.2%) 
Ovarian Cancer patients 
MUTYH M c.1145G>A 
p.Gly382A
sp 
PV 2 (50%) 
ATM IVS c.4776+1G>T / LPV 1 (25%) 
PMS2 M c.2249G>A 
p.Gly750A
sp 





























Table 9. Comparison of baseline characteristics and clinico-pathological information of BC patients analyzed 




All WT p-value* p-value** 
 
Number of patients 
 
83 24 589 / / 
































































































































































































































































Table 10.Comparison of baseline characteristics and clinico-pathological information of OC patients 
analyzed to BRCA1/2 and Multi-gene panel testing 
 BRCA1/2 Multi-gene Panel MUT All WT p value* p value** 
 
Number of patients 
 
85 4 283 / / 
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